Safety and efficacy of argatroban combined with antiplatelet therapy for acute mild-to-moderate ischemic stroke with large artery atherosclerosis
Open Access
- 27 November 2024
- journal article
- research article
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (1) , 108151
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Dual Antiplatelet Treatment up to 72 Hours after Ischemic StrokeNew England Journal of Medicine, 2023
- Effects of argatroban therapy for stroke patients: A meta-analysisJournal of Clinical Neuroscience, 2021
- Early and long-term outcomes of argatroban use in patients with acute noncardioembolic strokeClinical Neurology and Neurosurgery, 2020
- Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study)Journal of Stroke and Cerebrovascular Diseases, 2018
- Association between hyperhomocysteinemia and stroke with atherosclerosis and small artery occlusion depends on homocysteine metabolism-related vitamin levels in Chinese patients with normal renal functionMetabolic Brain Disease, 2017
- Comparison of Stroke Guidelines: Similarities and Differences between Japanese and European Recommendations for the Management and Prevention of Acute Ischemic and Hemorrhagic StrokesCerebrovascular Diseases, 2013
- Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised studyThe Lancet Neurology, 2007
- Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial StenosisNew England Journal of Medicine, 2005
- Argatroban Anticoagulation in Patients With Acute Ischemic Stroke (ARGIS-1)Stroke, 2004
- The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic strokeThe Lancet, 1997